Cell-cycle redistribution and Cdc2 phosphorylation in B16 cells
Cell-based study · B16 mouse melanoma cells in culture [1]
At 0.5 μM, PD0166285 shifted cells toward G0/G1 within 4 h and reduced Cdc2 Tyr15 phosphorylation. No apoptotic sub-G1 population was reported through 24 h; this endpoint does not establish overall cell survival.
| Endpoint | Reported result | Reference |
|---|---|---|
| G0/G1, S and G2 fractions | Reported observation 0 h: 67%, 16%, 17%; 4 h: 86%, 12%, 2% | [1] |
| Cdc2 Tyr15 phosphorylation | Reported observation Marked reduction after treatment; total Cdc2 remained similar | [1] |
| Apoptotic sub-G1 population | Reported observation No sub-G1 population reported at 24 h | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5 μM
- Exposure duration
- 0–4 h for redistribution/immunoblot; 24 h only for sub-G1 observation
- Method
- PI DNA-content flow cytometry and immunoblotting
- Vehicle
- DMSO control
- Co-treatment
- Single agent
- Reported limits
- Selected phase percentages lack a stated replicate count/uncertainty. Salt and lot characterization not specified.
Methods and source locations
Compound reported in the paper: PD0166285; Compound label in the paper: PD0166285
Named research compound in the reported model; no Adooq lot equivalence established.
Methods: Drug, Cell counting, Flow Cytometry and Cell Cycle Analysis, Immunoblotting; Results first/third subsections; Figures 1B and 3A; Discussion
G0/G1, S and G2 fractions: PI flow cytometry; at least 20,000 cells collected per analysis, not a biological replicate count. — Results first subsection; Figure 1B
Cdc2 Tyr15 phosphorylation: Immunoblot at 0, 2 and 4 h; total Cdc2 and actin controls shown. — Results third subsection; Figure 3A and caption
Apoptotic sub-G1 population: DNA-content flow cytometry; absence of this signal does not demonstrate viability. — Results first subsection; Figure 1B; Discussion